|

JAK Inhibitor Clinical Trials

2 actively recruiting trials across 1 location

Also known as: JAK inhibitors, Janus Kinase Inhibitor

Pipeline

Phase 2: 2

Top Sponsors

  • Shixiu Wu1
  • Fred Hutchinson Cancer Center1

Indications

  • Cancer2
  • Immune Checkpoint Inhibitors (ICI)-Related Dermatitis1
  • Secondary Myelofibrosis1
  • Primary Myelofibrosis1
  • Myelodysplastic/Myeloproliferative Neoplasm1

Other1 trial

JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial
Phase 2

Seattle, Washington1 trial

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.